Status: Not yet recruiting
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with moderate to severe HHT.
Participants needed: 240
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Vaderis Therapeutics AGUpdated: Aug 4, 2026
Eligibility criteria
Participants are ≥18 years of age at the Screening Visit. [+5]
History or current diagnosis of clinically significant electrocardiogram (ECG) a... [+4]